Professor Louise Emmett
Professor Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent's Hospital Sydney. She has been instrumental in developing the radiopharmacy initiative on the St Vincent's Campus and has introduced multiple new radioisotopes for clinical and research purposes. The St Vincent's Theranostics Department is highly published in both PET imaging and radionuclide therapy. Louise is heavily involved in multi-site multidisciplinary trials run across Australia, in addition to undertaking early phase clinical trials on the St Vincent's Campus. She believes in the power of clinical research to optimise treatments and improve lives.
Louise completed medical school at Auckland University (1992), New Zealand and received her FRACP qualification in Sydney, Australia (1999). She undertook a specialty fellowship in Nuclear Cardiology at the University Health Network in Toronto (2000), and completed a Doctorate of Medicine in Nuclear Cardiology through Auckland University in 2014. Since commencing work at St Vincent's Hospital in 2012, her focus has shifted to Theranostics. Happily this shift in focus (mid-life crisis) coincided with the first publication of PSMA imaging in a mouse. Louise is a clinical professor with the University of New South Wales. She has published over 80 original papers in peer reviewed journals in the last 10 years, has received a number of grants for clinical research and has presented at numerous national and international meetings.
Selected publications
See all publications- 2025Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.269252
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
- 2025Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.268901
Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
- 2025Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.268896
Diagnostic Potential of Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
- 2025The Lancet. Oncology10.1016/S1470-2045(25)00009-9
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
- 2025BJU International10.1111/bju.16608
Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.